Novartis has lined up two more neurologic diseases in its gene therapy collaboration with Voyager Therapeutics, this time paying about $100 million upfront to get its hands on capsids for Huntington’s disease and spinal muscular atrophy.
The Tuesday morning deal serves as a precursor to what is likely to be a pact-heavy JP Morgan Healthcare Conference next week. Voyager’s shares $VYGR were up 32% before Tuesday’s opening bell, rising to $11.21 apiece. As part of the deal, Novartis will buy $20 million worth of shares at $9.32 per share, Voyager disclosed in an SEC filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.